BIOSPECIFICS TECHNOLOGIES CORP
DelistedCIK 875622fmd_1AMETBQ01F58XZNXE7725NCMGZManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2009 to Sep 30, 2020, 43 periods
| Line item | FY2010 | FY2011 | FY2012 | FY2013 | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 6 | 11 | 11 | 14 | 14 | 23 | 26 | 27 | 33 | 38 |
| Research and development | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Operating income | (2) | 5 | 5 | 8 | 7 | 14 | 17 | 18 | 23 | 28 |
| Interest expense | 0 | 0 | – | – | – | – | – | – | – | – |
| Interest and investment income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 2 |
| Other non-operating income (expense) | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 2 |
| Income before taxes | (2) | 5 | 5 | 8 | 7 | 15 | 17 | 18 | 25 | 30 |
| Income tax expense | 0 | (1) | 2 | 3 | 2 | 5 | 6 | 7 | 5 | 6 |
| Net income from continuing operations | (2) | 7 | 3 | 5 | 5 | 10 | 11 | 11 | 20 | 24 |
| Net income | (2) | 7 | 3 | 5 | 5 | 10 | 11 | 11 | 20 | 24 |